Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal LKA651 vs ranibizumab in diabetic macular edema
2018-000031-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LKA651 in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Best Corrected Visual Acuity at week 12. Started Oct 2018; status: completed.
02
Drugs
LKA651
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2018-000031-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000031-28.